Title:
【発明の名称】リポソーム組成物およびそれらの利用方法
Document Type and Number:
Japanese Patent JP2002515856
Kind Code:
A
Abstract:
The present invention provides a pharmaceutical composition, kit, and method of forcing the reverse transport of cholesterol from peripheral tissues to the liver in vivo while controlling plasma LDL concentrations. The method includes the step of administering a therapeutically effective amount of a multiplicity of large liposomes comprised of phospholipids substantially free of sterol for a treatment period. The method optionally includes the step of periodically assaying plasma LDL concentrations with an assay during the treatment period to assess plasma atherogenic lipoprotein concentrations and obtain an atherogenic lipoprotein profile, and adjusting the administration in response to said profile. The large liposomes are dimensioned larger than fenestrations of an endothelial layer lining hepatic sinusoids in the liver so that the liposomes are too large to readily penetrate the fenestrations. The therapeutically effective amounts are in the range of about 10 mg to about 1600 mg phospholipid per kg body weight per dose. A pharmaceutical composition and related kit for mobilizing peripheral cholesterol and sphingomyelin that enters the liver of a subject consisting essentially of liposomes of a size and shape larger than fenestrations of an endothelial layer lining hepatic sinusoids in the liver is also provided.
Inventors:
Williams Kevin John
Application Number:
JP51526397A
Publication Date:
May 28, 2002
Filing Date:
October 11, 1996
Export Citation:
Assignee:
Taralia Therapeutics Inc.
International Classes:
G01N33/544; A61K9/00; A61K9/127; A61K9/14; A61K31/01; A61K35/14; A61K48/00; A61M1/14; A61M1/36; A61P1/16; A61P9/10; C12P19/34; A61M1/16; A61M1/28; A61M1/34; (IPC1-7): A61K9/127; A61K48/00; A61M1/14; A61M1/36; A61P1/16; A61P9/10; G01N33/544
Attorney, Agent or Firm:
Tetsuro Toriumi